|
|
 |
|
Viewing report
|
|
|
|
Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad
John Wiley and Sons Ltd, Jan 2010, Pages: 876
The science and applied approaches of enzyme inhibition in drug discovery and development
Offering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, Enzyme Inhibition in Drug Discovery and Development examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development.
With chapters written by over fifty leading experts in their fields, Enzyme Inhibition in Drug Discovery and Development fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the 'good' inhibitions—desirable pharmacological effects—and 'bad' inhibitions—drug–drug interactions and toxicity. The book discusses:
- The drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment
- The manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drug–drug interactions
- The inhibition of several major drug target pathways, such as the GPCR pathway, the NFB pathway, and the ion channel pathway
Through this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Personalized Medicine - Scientific and Commercial Aspects
Drug Metabolism Handbook: Concepts and Applications
Preclinical Models: Innovative Solutions to Accelerate Drug Discovery and Development
The Biochemistry of Drug Metabolism: Two Volume Set
Alzheimer Disease - New Drugs, Markets and Companies
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Polypharmacology in Drug Discovery
HIV-1 Integrase: Mechanism and Inhibitor Design
Protein Kinases as Drug Targets
Cancer Drug Resistance
|
|
|
|
